Zymeworks (NASDAQ:ZYME) Shareholders Are up 9.5% This Past Week, but Still in the Red Over the Last Three Years

Zymeworks Inc. (NASDAQ:ZYME) shareholders should be happy to see the share price up 19% in the last month. But that doesn't change the fact that the returns over the last three years have been

Simply Wall StJul 18 15:27 ET

Zymeworks to Unveil Q2 2024 Results and Drug Progress

TipRanksJul 11 07:09 ET

Zymeworks To Report Second Quarter 2024 Financial Results and Host Conference Call on August 1, 2024

VANCOUVER, British Columbia, July 11, 2024 (GLOBE NEWSWIRE) -- Zymeworks Inc. (NASDAQ:ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the

GlobeNewswireJul 11 06:30 ET

H.C. Wainwright Maintains Zymeworks(ZYME.US) With Hold Rating, Maintains Target Price $10

H.C. Wainwright analyst Robert Burns maintains $Zymeworks(ZYME.US)$ with a hold rating, and maintains the target price at $10.According to TipRanks data, the analyst has a success rate of 24.0% and a

moomoo NewsJun 18 06:31 ET · Ratings

Zymeworks Analyst Ratings

Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 06/18/2024 17.1% HC Wainwright & Co. $10 → $10 Reiterates Buy → Buy 06/06/2024 17.1% HC Wainwright & Co. $

BenzingaJun 18 06:12 ET

Zymeworks ZW171 IND for Mesothelin-expressing Cancers Cleared by FDA

Seeking AlphaJun 17 14:49 ET